RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory RequirementsColombia is the third Latin American market in which Cellgenic has recently announced local commercial arrangements. Activity remains subject to applicable Colombian law and the terms of local contracts. This announcement does not forecast revenue and does not mean product registration is complete.
Cellgenic Establishes Local Commercial Presence in BrazilCellgenic is expanding local representation and commercial support in Brazil, one of Latin America's larger healthcare and aesthetic-medicine markets. ISSCA continues to hold physician-education events in São Paulo. Activities in Brazil remain subject to applicable local law and regulatory requirements.
RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American FootprintPeru becomes the newest addition to Cellgenic's Latin American commercial network - one of three coordinated market initiatives across the region, subject to applicable local regulatory requirements.
RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International RegionsA second cellular-technology launch in close succession broadens Cellgenic's portfolio into Latin America, the Middle East, Europe, and Southeast Asia, demonstrating a repeatable product-development motion.
RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder EngagementNew Website Serves as a Central Source for Investor Information and Timely Disclosure; Investor Inquiries Directed to ir@rmtg.com
RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International MarketsNew NK cell platform extends RMTG's cellular-technology portfolio into immunology-adjacent applications, with an initial commercial focus on Latin America and Southeast Asia.
RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000Continued Acceleration in 2026 With Record Revenue, Expanding Margins, Growth in Operating Profit, and Accelerating Training and Product Supply Sales
RMTG Provides Details for First-Ever Investor Call to Answer Shareholder QuestionsCompany Announces Date, Time and Connection Details for Its Inaugural Investor Call Following a Strong First Half of 2026
RMTG Expands Cellgenic's Cancún Laboratory Infrastructure with Two Additional ISO 7 Clean RoomsAn owned-infrastructure investment adds manufacturing, quality-systems, and product-development capacity to support Cellgenic's growing international product portfolio.
RMTG to Hold First-Ever Investor Call to Discuss Second Quarter 2026 ResultsA Positive First Half of 2026 Prompts the Company to Launch Its First Investor Call and Invite Shareholder Questions
RMTG Expands Cellgenic Operations Into Argentina, Establishing a Strategic Commercial Hub for Regenerative Medicine in Latin AmericaCellgenic Launches Regulated Commercial Operations in Argentina, Creating a Platform for Biologics Distribution, Physician Education, and Regional Expansion Across Latin America
RMTG Launches ISSCA AI(TM) Clinical Intelligence Platform, Extending Its Global Regenerative Medicine Network Into AI-Driven Clinical InfrastructureNew AI Platform Builds on a 30+ Country Physician Network and the ISSCA Mobile App to Create a Connected, Technology-Enabled Ecosystem for Regenerative and Longevity Medicine
Global Stem Cells Group (OTC:RMTG) Launches ISSCA Mobile App, Advancing Its Buildout of a Global Digital Ecosystem for Regenerative MedicineNew physician-facing platform digitizes a 30+ country network and lays the foundation for ISSCA AI™, positioning RMTG at the intersection of regenerative medicine and scalable health technology
